Impaired endothelial function in arterial hypertension and hypercholesterolemia: Potential mechanisms and differences

Journal of Hypertension

Volumn 18, Issue 4, 2000, Pages 363-374

  John, Stefan ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Atherosclerosis; Endothelial function; Hypercholesterolemia; Hypertension; Nitric oxide

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; INDOMETACIN; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCARINIC RECEPTOR; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PROSTAGLANDIN SYNTHASE; STATIN; SUBSTANCE P; SUPEROXIDE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ATHEROGENESIS; ATHEROSCLEROSIS; BIOAVAILABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; ENDOTHELIUM LESION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

EID: 0034037024     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018040-00002     Document Type: Review

References (149)

1. 1 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
2. 2 Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323:27-36.
3. 3 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
4. 4 Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666.
5. 5 Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
6. 6 Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2:997-1000.
7. 7 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
8. 8 De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96:60-68.
9. 9 Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15:1652-1659.
10. 10 Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost 1993; 70:36-41.
11. 11 Draijer R, Atsma DE, Van der Laarse A, van Hinsbergh VW. CGMP and nitric oxide modulate thrombin-induced endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 1995; 76:199-208.
12. 12 Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
13. 13 Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994; 267:C1405-C1413.
14. 14 Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14:753-759.
15. 15 Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 90:1585.
16. 16 Anggard E. Nitric oxide: mediator, murderer and medicine. Lancet 1994; 343:1199-1206.
17. 17 Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-1115.
18. 18 Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, et al. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis.
19. 19 Vanhoutte PM. How to assess endothelial function in human blood vessels. J Hypertens 1999; 17:1047-1058.
20. 20 Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25:918-923.
21. 21 Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the coronary and peripheral circulations. J Am Coll Cardiol 1995; 26:1235-1241.
22. 22 Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
23. 23 Linder L, Kiowsky W, Buhler FR, Luscher TF. Direct evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted responses in essential hypertension. Circulation 1990; 81:1762-1767.
24. 24 Brush JE Jr, Faxon DP, Salmon S, Jakobs AK, Ryan TJ. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992; 19:809-815.
25. 25 Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH, et al. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 1992; 71:776-781.
26. 26 Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21:929-933.
27. 27 Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87:86-93.
28. 28 Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24:16-23.
29. 29 Nitenberg A, Antony I, Aptecar E, Arnoult F, Lerebours G. Impairment of flow-dependent coronary dilation in hypertensive patients. Demonstration by cold pressor test induced flow velocity increase. Am J Hypertension 1995; 8:13S-18S.
30. 30 Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with arterial hypertension. Different responses to acetylcholine and substance P. Hypertension 1995; 25:201-206.
31. 31 Kelm M, Preik M, Hafner DJ, Strauer BE. Evidence for a multifactorial process involved in the impaired flow response to nitric oxide in hypertensive patients with endothelial dysfunction. Hypertension 1996; 27:346-353.
32. 32 Cockroft JR, Chowiencczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med 1994; 330:1036-1040.
33. 33 Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86:228-234.
34. 34 Vita JA, Treasure CB, Nabel EG, McIenachan JM, Fish RD, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81:491.497.
35. 35 Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992; 340:1430-1432.
36. 36 Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88:2541-2547.
37. 37 Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation 1993; 88:2139-2148.
38. 38 Chowienczyk PJ, Watts GF, Cockroft JR, Brett SE, Ritter JM. Sex differences in endothelial function in normal and hypercholesterolaemic subjects. Lancet 1994; 344:305-306.
39. 39 Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon III RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90:35-41.
40. 40 Stroes ESG, Koomans HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346:467-471.
41. 41 Casino PR, Kilcoyne CM, Cannon III RO, Quyyumi AA, Panza JA. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor. Am J Cardiol 1995; 75:40-44.
42. 42 Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10:1025-1031.
43. 43 Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
44. 44 Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29:274-279.
45. 45 Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349:837-842.
46. 46 John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients - a randomized, placebo-controlled, double-blind study. Circulation 1998; 98:211-216.
47. 47 Taddei S, Viridis A, Mattei P, Ghiadoni L, Gennari A, Basile-Fasolo C, et al. Aging and endothelial function in normotensive subjects and essential hypertensive patients. Circulation 1995; 91:1981-87.
48. 48 Taddei S, Virdis A, Mattei P, Ghiadoni L, Basile-Fasolo C, Sudano I, et al. Hypertension causes premature aging of endothelial functions in humans. Hypertension 1997; 29:736-743.
49. 49 Panza JA, Casino PR, Badar DM, Quyyumi AA, Effects of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87:1475-1481.
50. 50 Imaizumi T, Hirooka Y, Masaki H, Harada S, Momohara S, Tagawa T, et al. Effects of L-arginine on forearm vessels and responses to acetylcholine. Hypertension 1992; 20:511-517.
51. 51 Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546-1550.
52. 52 Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90:1248-1253.
53. 53 Arnal JF, Munzel T, Venema RC, James NL, Bai CL, Mitch WE, et al. Interactions between L-arginine and L-glutamine change endothelial NO production: an effect independent of NO synthase substrate availability. J Clin Invest 1995; 95:2565-2572.
54. 54 Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
55. 55 Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219:598-603.
56. 56 Cooke JP, Tsao PS. Arginine: a new therapy for atherosclerosis? Circulation 1997; 95:311-312.
57. 57 Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction - its role in hypercholesterolemia. Circulation 1998; 98:1842-1847.
58. 57 Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141-1146.
59. 59 Okumura K, Yasue H, Ishizaka H, Ogawa H, Fujii H, Yoshimura M. Endothelium-dependent dilator response to substance P in patients with coronary spastic angina. J Am Coll Cardiol 1992; 20:833-844.
60. 60 Saito R, Nonaka S, Konishi H, Takano J, Shimohigashi Y, Matsumoto H, et al. Pharmacological properties of the tachykinin receptor subtype in the endothelial cell and vasodilation. Ann NY Acad Sci 1991; 632:457-459.
61. 61 Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994; 23:1610-1616.
62. 62 Casino PR, Kilcoyne CM, Cannon III RO, Quyyumi AA, Panza JA. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor. Am J Cardiol 1995; 75:40-44.
63. 63 Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal tranduction pathway. Circulation 1995; 91:1732-1738.
64. 64 Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA Cannon III RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90:35-41.
65. 65 Freeman JE, Kuo WY, Drenger B, Barnett TN, Levine MA, Flavahan NA. Analysis of lysophosphatidylcholine-induced endothelial dysfunction. J Cardiovasc Pharmacol 1996; 28:345-352.
66. 66 Liao JK, Clark SL. Regulation of G-protein alpha (i2) subunit expression by oxidized low-density lipoprotein. J Clin Invest 1995; 95:1457-1463.
67. 67 Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon III RO, Panza JA. Decreased vasodilator response to isoproterenol during nitric oxide inhibition in humans. Hypertension 1997; 30:918-921.
68. 68 Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon RO III, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 1998; 97:851-856.
69. 69 Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 1996; 7:274-280.
70. 70 Rosenkranz-Weiss P, Sessa WC, Milstein S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells: elevations in tetrahydrobiopterin levels enhance endothelial nitric oxiden synthase specific activity. J Clin Invest 1994; 93:2236-2243.
71. 71 Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
72. 72 Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96:3264-3265.
73. 73 Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. Hypertens Res 1995; 18:87.98.
74. 74 Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996; 271:C1424-C1437.
75. 75 Rubanyi GM, Vanhoutte PM. Superoxide anions and hypoxia inactivate endothelium derived relaxing factor. Am J Physiol 1986; 250:H822-H827.
76. 76 Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium derived vascular relaxing factor. Nature 1986; 320:456-456.
77. 77 Ohara Y, Peterson TE, Harrison GD. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91:2546-2551.
78. 78 Mügge A, Brandes RP, Böger RH, Dwenger A, Bode-Böger S, Kienke S, et al. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994; 24:994-998.
79. 79 Mügge A, Helwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxation in cholesterolfed rabbits. Circ Res 1991; 69:1293-1300.
80. 80 Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88:10045-10048.
81. 81 Garcia CE, Kilcoyne CM, Cardillo C, Cannon III RO, Quyyumi AA, Panza JA. Effect of copper-zinc superoxide dismutase on endothelium-dependent vasodilation of patients with essential hypertension. Hypertension 1995; 26:863.868.
82. 82 Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96:1513-1519.
83. 83 Taddei S, Virdis A, Ghiadoni L, Magnagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97:2222-2229.
84. 84 Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95:2617-2622.
85. 85 Green D, O'Driscoll G, Rankin JM, Maiorana AJ, Taylor RR. Beneficial effect of vitamin E administration on nitric oxide function in subjects with hypercholesterolemia. Clin Sci 1998; 95:361-367.
86. 86 Neunteufl T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, Weidinger F. Additional benefit of vitamin E supplementation to simvastatin on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol 1998; 32:711-716.
87. 87 Heitzer, Yla Herttuala S, Wild E, Luoma J, Drexler H. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol 1999; 33:499-505.
88. 88 Mietus-Snyder M, Malloy MJ. Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy. J Pediatr 1998; 133:35-40.
89. 89 Gilligan DM, Sack MN, Guetta V, Casino PR, Quyyumi AA, Rader DJ, et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994; 24:1611-1617.
90. 90 Chowienczyk PJ, Kneale BJ, Brett SE, Paganga G, Jenkins BS, Ritter JM. Lack of effect of vitamin E on L-arginine-responsive endothelial dysfunction in patients with mild hypercholesterolemia and coronary artery disease. Clin Sci 1998; 94:129-134.
91. 91 Friedl HP, Till GO, Ryan US, Ward PA. Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J 1989; 3:2512-2518.
92. 92 Bulkey GB. Reactive oxygen metabolites and reperfusion injury: aberrant triggering of reticuloendothelial function. Lancet 1994; 344:934-936.
93. 93 Cardillo C, Kilcoyne CM, Cannon RO, Quyyumi AA, Panza JA. Xanthine oxidase inhibition improves endothelium-dependent vasodilation in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30:57.63.
94. 94 Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46:325-415.
95. 95 Boulanger CM, Tanner FC, Bea ML, Hahn AWA, Wener A, Lüscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992; 70:1191-1197.
96. 96 Schneider MP, Hilgers KF, Klingbeil AU, John S, Veelken R, Schmieder RE. Plasma endothelin is increased in early essential hypertension. Am J Hypertens; in press.
97. 97 Pritchard KA, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77:510-518.
98. 98 Mayer B, John M, Werner ER, Wachter H, Schultz G, Böhme E. Brain nitric oxide synthase is a biopterin-and flavin-containing multifunctional oxidoreductase. FEBS Lett 1991; 288:187-191.
99. 99 Kwon NS, Nathan CF, Stuher DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989; 264:20496-20501.
100. 2+/calmodullin dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992; 281:627-630.
101. 101 Cosentino F, Katusic Z. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995; 91:139-144.
102. 102 Schmidt K, Werner ER, Mayer B, Wachter H, Kukovetz WR. Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells. Biochem J 1992; 281:297-300.
103. 103 Gorren ACF, List BM, Schrammel A Pitters E, Hemmens B, Werner ER, et al. Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites. Biochem 1996; 35:16735-16745.
104. 104 Wever RMF, Van Dam T, van Rijn HJM, De Groot PG, Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthesis. Biochem Biophys Res Commun 1997; 237:340-344.
105. 105 Stroes ESG, Kastelein JJ, Cosentino F, Erkelens DW, Wever R, Koomans HA, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99:41-46.
106. 106 Moro MA, Darley-Usmar VM, Lizasoain I, Su Y, Knowles RG, Radomski MW, et al. The formation of nitric oxide donors from peroxynitrite Br J Pharmacol 1995; 116:1999-2004.
107. 107 Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide and superoxide. Am J Physiol 1995; 268:L699-L722.
108. 108 Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87:1620-1624.
109. 109 Ischiropoulos H, Al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications FEBS Lett. 1995; 364:279-282.
110. 110 Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ Res 1994; 74:1141-1148.
111. 111 Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95:473-478.
112. 112 Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18:1433-1439.
113. 113 Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Schölkens BA, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol (Heart Circ Physiol) 1997; 41:H2701-2707.
114. 114 Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the reninangiotensin system. Circulation 1999; 99:2027-2033.
115. 115 Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995; 75:582-586.
116. 116 John S, Delles C, Klingbeil AU, Jacobi J, Schlaich MP, Schmieder RE. LDL-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. J Hypertens 1999; 17: 1933-1939.
117. 127 Flesch M, Sachinidis A, Ko Y, Kraft K, Vetter H. Plasma lipids and lipoproteins and essential hypertension. Clin Invest 1994; 72:944-950.
118. 118 Bochkov VN, Tkachuk VA, Hahn AWA, Bernhardt J, Buhler FR, Resink TJ. Concerted effects of lipoproteins and angiotensin II on signal transduction processes in vascular smooth muscle cells. Arterioscler Thromb 1993; 13:1261-1269.
119. 119 Abetel G, Poget PN, Bonnabry JP. Antihypertensive effect of a cholesterol-lowering agent (fluvastatin). Pilot study. Schweiz Med Wochenschr 1998; 128:272-277.
120. 120 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
121. 121 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1350-1351.
122. 122 Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341:1496-1500.
123. 123 Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
124. 124 Treasure CB, Klein L, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
125. 125 Stroes ESG, Koomans HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346:467-471.
126. 126 Wassmann S, Nickenig G, Böhm M. Atorvastatin downregulates AT1-receptor gene expression and cell proliferation in vascular smooth muscle cells. J Am Coll Cardiol 1999; 33 (suppl A):222A.
127. 127 Laufs U, La Fata V, Plutzky J, Liao K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-1135.
128. 128 Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33:234-241.
129. 129 O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-1131.
130. 130 Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997; 95:76-82.
131. 131 Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R, et al. Improvement of coronary vasodilation capacity through single LDL apharesis. Atherosclerosis 1998; 139:173-178.
132. 132 Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999; 99:3227-3233.
133. G-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994; 12:1047-1052.
134. 134 Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21:1145-1151.
135. 135 Cockroft JR, Chowienczyk PJ, Brett SE, Chen C, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274:1067-1071.
136. 136 Frielingsdorf J, Seiler C, Kauffman P, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996; 93:1380-1387.
137. 137 Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30:1606-1612.
138. 138 Mak TI, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Circ Res 1992; 70:1099-1103.
139. 139 Virdis A, Taddei S, Buralli S, Ghiadoni L, Magagna A, Salvetti A. Nifedipine improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Am J Hypertens 1999; 12 (suppl):57A.
140. 140 Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94:3115-3122.
141. 141 Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin converting enzyme inhibition with qinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94:258-265.
142. 142 Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24:499-505.
143. 143 Kiowski W, Linder L, Nuesch R, Martina B. Effect of cilazapril on vascular structure and function in essential hypertension. Hypertension 1996; 27:371-376.
144. 144 Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilation in essential hypertensive patients. J Hypertens 1998; 16:447-456.
145. 145 Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman B, Griendling K, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alteration of vasomotor tone. J Clin Invest 1996; 97:1916-23.
146. 146 Dijkhorst-Oei LT, Stroes ES, Koomans HA, Rabelink TJ. Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. J Cardiovasc Pharmacol 1999; 33:420-424.
147. 147 Maeso R, Navarro-Cid J, Munoz-Garcia R, Rodrigo E, Ruilope LM, Lahera V, et al. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Hypertension 1996; 28:967-972.
148. 148 Wiemer G, Scholkens BA, Busse R, Wagner A, Heitsch H, Linz W. The functional role of angiotensin II subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 1993; 3:24-27.
149. 149 Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediated nitric oxide release after angiotensin receptor stimulation. Hypertension 1995; 26:164-170.